Sunday, August 3, 2025 8/3/2025

OPTIMIZATION OF U1 ADAPTOR TECHNOLOGY

Award Number: R44GM085863
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/15/2008
PERIOD OF PERFORMANCE END DATE: 01/31/2013

Group Awards By:

View Award Description

OPTIMIZATION OF U1 ADAPTOR TECHNOLOGY - DESCRIPTION (provided by applicant): Our understanding of complex biological phenomena and disease progression has led to the realization that changes in the expression of genes underlie many of these processes. Developing reagents that can selectively alter the expression level of any desired gene has been a goal of both scientists and clinicians for years. Historically, the most common approach was based on antisense oligonucleotides (ASOs) that encompass a broad variety of mechanisms that have in common an oligonucleotide designed to base pair with its complementary target mRNA leading to either degradation or impaired function of the mRNA. Classically, ASOs were designed to interfere with translation of the target mRNA or induce its degradation via RNase H. Currently, greater excitement has focused on RNAi which uses a distinct mechanism where oligonucleotides trigger an endogenous pre-existing gene suppression pathway that is fundamental to cellular gene regulatory networks. In spite of its general success, some mRNAs are only modestly downregulated (2-fold) by RNAi and others may be refractory. Further, certain off-target effects can arise leading to unexpected consequences, underscoring the need for additional methods. The rapid rise of the RNAi field has led to an increased appreciation, of direct relevance to the present proposal, that regulatory sequence elements in mRNA 3' ends (i.e., 3'UTRs) control the expression of that gene. Here we present a progress report from a Phase 1 SBIR on the development of a new gene silencing technology which we call "U1 Adaptors," that uses oligonucleotides annealing to specific sequence regions within the 3'UTR to inhibit pre-mRNA processing. In this Phase 2 proposal, we plan to continue the optimization work begun in Phase 1 and expand to perform high throughput analysis of U1 Adaptors to establish site selection criteria and create an algorithm and design tool to assist with application of this technology to new gene targets with ease. We further propose to test the specificity of the method using whole genome microarray analysis. We intend to focus on use of this technology in genes which appear to be difficult to suppress using RNAi methods. Finally, we propose to study use of U1 Adaptors in complex genes having more than one polyadenylation site or alternative splicing involving the terminal exon. We believe this new technology will make a significant addition to our gene silencing toolkit and may even aid emerging oligonucleotide- based therapies, although that is beyond the scope of this proposal. PUBLIC HEALTH RELEVANCE: The commercialization of this new U1 Adaptor mediated gene silencing technology will be a significant addition to the scientific research community's "gene silencing toolkit". Because this method exploits a distinctly different mechanism compared to more common gene silencing approaches, it has the potential of enhancing these traditional technologies when used in combination with them via additive effects. This may aid in the development of emerging oligonucleotide-based gene silencing therapies by improving sensitivity and efficacy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2012 ( Subtotal = $0 )
2012	2011	INTEGRATED DNA TECHNOLOGIES INC	1710 COMMERCIAL PARK	CORALVILLE	IA	52241	JOHNSON	USA	Biomedical Research and Research Training	000	3	2/10/2012	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2011 ( Subtotal = $407,279 )
2011	2011	INTEGRATED DNA TECHNOLOGIES INC	1710 COMMERCIAL PARK	CORALVILLE	IA	52241	JOHNSON	USA	Biomedical Research and Research Training	000	3	1/21/2011	NON-COMPETING CONTINUATION	$407,279
														Subtotal = $407,279

Issue Date FY: 2010 ( Subtotal = $460,941 )
2010	2010	INTEGRATED DNA TECHNOLOGIES INC	1710 COMMERCIAL PARK	CORALVILLE	IA	52241	JOHNSON	USA	Biomedical Research and Research Training	000	2	1/29/2010	COMPETING CONTINUATION	$460,941
														Subtotal = $460,941

Grand Total All Awards = $868,220

Top

All Categories

About

Search

Reports

Data Submission

Award Information

OPTIMIZATION OF U1 ADAPTOR TECHNOLOGY

Award Number: R44GM085863

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/15/2008

PERIOD OF PERFORMANCE END DATE: 01/31/2013

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer